CallaghanRDesmondPVPaullPMashfordML. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis. Hepatology1993; 18: 54–60.
2.
EdgintonANWillmannS. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet2008; 47: 743–752.
3.
KostopanagiotouGMarkantonisSLArkadopoulosNAndreadouICharalambidisGChondroudakiJ. The effect of acutely induced hepatic failure on remifentanil and fentanyl blood levels in a pig model. Eur J Anaesthesiol2006; 23: 598–604.
4.
PughRNMurray-LyonIMDawsonJLPietroniMCWilliamsR. Transection of the oesophagus for bleeding oesophagealvarices. Br J Surg1973; 60: 646–649.
5.
RileyJEisenbergEMüller-SchwefeGDrewesAMArendt-NielsenL. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin2008; 24: 175–192.
6.
TegederILötschJGeisslingerG. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet1999; 37: 17–40.
7.
VerbeeckRK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol2008; 64: 1147–1161.
